每经AI快讯，步长制药1月27日晚间发布业绩预告，预计2025年年度实现归属于母公司所有者的净利润 约为3.2亿元到4.68亿元，与上年同期相比，将实现扭亏为盈。 免责声明：本文内容与数据仅供参考，不构成投资建议，使用前请核实。据此操作，风险自担。 每日经济新闻 每经头条（nbdtoutiao）——国际金价冲破5000美元！7年涨了280%，什么时候才见顶？专家：关键还 看美元，重点关注国际货币体系、降息和科技革命 （记者 王瀚黎） ...

Core Viewpoint - The A-share pharmaceutical sector has gained renewed investor interest due to the resurgence of COVID-19 cases in India, leading to fluctuations in the Chinese medicine ETF (560080) and notable stock performance among key companies in the sector [1][6]. Group 1: Market Performance - The Chinese medicine ETF (560080) experienced a nearly 2% decline on January 27, following a more than 1.4% increase the previous day, with trading volume surpassing 85 million yuan [1]. - Notable declines were observed in key stocks within the ETF, including Zhongsheng Pharmaceutical down over 7% and Yiling Pharmaceutical down over 5%, with several others also experiencing declines [3]. Group 2: Valuation Insights - The latest price-to-earnings ratio (PE TTM) for the index tracked by the Chinese medicine ETF (560080) is 24.57, indicating that the valuation is below 81.27% of the time since the index was published in May 2015, suggesting a favorable valuation opportunity [4]. Group 3: Company News - Zhongsheng Pharmaceutical announced a projected net profit of 260 million to 310 million yuan for 2025, marking a significant turnaround with an increase of 186.91% to 203.62% year-on-year [7]. - Yiling Pharmaceutical also forecasted a net profit of 1.2 billion to 1.3 billion yuan for 2025, indicating a key operational turning point [7]. - Kangyuan Pharmaceutical received approval for clinical trials of a new traditional Chinese medicine aimed at treating children's adenoid hypertrophy, marking a step forward in innovation [7]. Group 4: Industry Trends - The Chinese traditional medicine market is projected to exceed 700 billion yuan in 2024, driven by stable demand amid an aging population, although pricing volatility has been influenced by inventory adjustments and procurement policies [8]. - The industry is experiencing a consolidation trend, with leading companies capturing over half of the market revenue and profits, while ongoing policy focus on innovation and quality development is reshaping the competitive landscape [8].

Core Viewpoint - The company acknowledges that its stock price is influenced by various factors including macroeconomic environment, industry cycles, and fluctuations in the secondary market [2] Group 1 - The company emphasizes its commitment to enhancing operational performance and management standards [2] - The company aims to create value for its shareholders [2]

证券日报网讯1月26日，九芝堂（000989）在互动平台回答投资者提问时表示，根据公司《2025年半年 度报告》披露：中药经典名方YB106、YB107按项目研发计划正常推进。如有重大进展公司将根据信息 披露的相关规定进行公告。 ...

Core Viewpoint - Yiling Pharmaceutical has demonstrated strong resilience in its performance amidst industry transformation and market fluctuations, with a significant turnaround in profitability expected for 2025 [1][7]. Financial Performance - The company forecasts a net profit attributable to shareholders of 1.2 billion to 1.3 billion yuan for 2025, marking a substantial recovery from a loss of approximately 724.5 million yuan in the previous year [3][9]. - The basic earnings per share are projected to be between 0.72 yuan and 0.78 yuan, compared to a loss of 0.43 yuan per share in the prior year [3][9]. - In Q3 2025, Yiling achieved an operating income of 1.827 billion yuan, a year-on-year increase of 3.78%, ending a streak of revenue declines [4][10]. - The net profit attributable to shareholders for Q3 2025 surged by 1264.61% to 332 million yuan, setting a historical high for the same period [4][10]. - Cumulatively, the net profit for the first three quarters exceeded 1 billion yuan, reflecting an 80.33% year-on-year growth, with a non-recurring net profit of 966 million yuan, up 90.53% [4][10]. Operational Efficiency - The gross profit margin for the first three quarters of 2025 rose to 60.53%, an increase of 7.14 percentage points from the previous year, indicating a recovery to normal levels [4][10]. - The company has implemented lean management practices, resulting in a 19.03% reduction in sales expenses year-on-year, optimizing its cost structure [4][10]. - The net profit margin for the first three quarters reached 16.99%, only slightly below the peak period of 2022, indicating a significant expansion in profitability [4][10]. Cash Flow and R&D Investment - Operating cash flow for the first three quarters of 2025 reached 1.278 billion yuan, a substantial increase of 296.19%, exceeding net profit and indicating improved operational quality [5][10]. - Yiling maintained a high R&D expenditure of 544 million yuan in the first three quarters, with a research expense ratio of 9.27% [6][11]. - Cumulatively, the company has invested over 5 billion yuan in R&D, establishing a sustainable innovation pipeline [6][11]. - The recent approval of the new chemical drug Wan Shuan® marks a significant breakthrough in the chemical drug sector, with multiple new traditional Chinese medicine products entering the application phase [6][11]. Strategic Outlook - Yiling Pharmaceutical's financial improvements and innovative advancements reflect its strategic execution and commitment to long-term growth [6][11]. - The company aims to leverage the health China strategy to create sustainable value for investors and society, demonstrating its ability to navigate industry cycles and maintain growth certainty [6][11].

Investment Rating - The report maintains an "Outperform" rating for the pharmaceutical and biotechnology sector [5] Core Views - The pharmaceutical sector underperformed the overall market, with a 0.39% decline in the biopharmaceutical sector compared to a 1.17% increase in the total A-share market [32] - The TTM price-to-earnings ratio for the pharmaceutical sector is 38.51x, which is at the 84.35th percentile of the historical valuation over the past five years [32][37] - The report highlights a shift in fund holdings, with a decrease in the proportion of pharmaceutical holdings in both pharmaceutical and non-pharmaceutical funds [11][16] Summary by Sections Market Performance - The overall A-share market increased by 1.17%, while the Shanghai and Shenzhen 300 index decreased by 0.62% [32] - The biopharmaceutical sector's performance was weaker than the overall market, with specific declines in chemical pharmaceuticals (-1.11%) and medical services (-2.17%) [32] Fund Holdings Analysis - As of Q4 2025, the net asset value of pharmaceutical funds reached 358.4 billion, a decrease of 9.0% from the previous quarter [11] - The proportion of pharmaceutical holdings in all funds was 7.97%, down 1.71 percentage points [16] - The largest sub-sectors by holdings were chemical preparations (37.5%) and other biological products (20.8%) [19] Company Earnings Forecasts and Ratings - Key companies such as Mindray Medical (237 billion market cap, "Outperform" rating) and WuXi AppTec (293.6 billion market cap, "Outperform" rating) are highlighted for their strong earnings forecasts [4] - The report lists several companies with projected earnings growth, including Aier Eye Hospital and New Industry, both rated "Outperform" [4] Investment Strategy - The report recommends focusing on innovative drugs and the CXO sector, emphasizing the competitive advantages of Chinese companies in the chemical CDMO space [41] - A portfolio of recommended stocks includes Mindray Medical, WuXi AppTec, and Aier Eye Hospital, among others [42][43]

Group 1 - The core transaction of Yunnan Baiyao on January 26 involved a block trade of 657,700 shares, amounting to 36.02 million yuan, with a transaction price of 54.77 yuan, reflecting a discount of 2.49% compared to the closing price of the day [2][3] - The closing price of Yunnan Baiyao on the same day was 56.17 yuan, showing a slight increase of 0.04%, with a turnover rate of 0.62% and a total trading volume of 614 million yuan, indicating a net outflow of 11.25 million yuan in main funds [2][3] - Over the past five days, Yunnan Baiyao's stock has seen a cumulative decline of 0.09%, while the total net inflow of funds during this period was 198 million yuan [2][3] Group 2 - The latest margin financing balance for Yunnan Baiyao is 1.266 billion yuan, which has decreased by 9.799 million yuan over the past five days, representing a decline of 0.77% [3] - Yunnan Baiyao Group Co., Ltd. was established on November 30, 1993, with a registered capital of 17.84262603 billion yuan [3]

Group 1 - The traditional Chinese medicine sector saw an increase of 0.9% on January 26, with Te Yi Pharmaceutical leading the gains [1] - The Shanghai Composite Index closed at 4132.61, down 0.09%, while the Shenzhen Component Index closed at 14316.64, down 0.85% [1] - Key stocks in the traditional Chinese medicine sector showed significant price movements, with Te Yi Pharmaceutical rising by 10.01% to a closing price of 13.19 [1] Group 2 - The traditional Chinese medicine sector experienced a net inflow of 594 million yuan from institutional investors, while retail investors saw a net outflow of the same amount [2] - The top gainers included Te Yi Pharmaceutical, which had a net inflow of 286 million yuan, accounting for 37.60% of the total [3] - Conversely, major losers included Wei Kang Pharmaceutical, which fell by 8.50% to a closing price of 29.40, with a trading volume of 86,100 shares [2]

Group 1 - The core point of the news is that Zhaoli Pharmaceutical conducted a block trade on January 26, with a total of 157,200 shares traded at a price of 13.62 yuan, which represents a discount of 22.22% compared to the market closing price of 17.51 yuan [1][2]. Group 2 - The transaction amount for the block trade was 2.1411 million yuan, accounting for 0.44% of the total trading volume on that day [1][2]. - The buyer of the shares was Bohai Securities Co., Ltd., while the seller was Guodu Securities Co., Ltd. [2].

Group 1 - The core transaction of Yunnan Baiyao involved a block trade of 657,700 shares, with a total transaction value of 36.0222 million yuan, accounting for 5.54% of the total trading volume on that day [1] - The transaction price was 54.77 yuan per share, which represents a discount of 2.49% compared to the market closing price of 56.17 yuan [1][2] - The buyer was from the brokerage unit of China Merchants Securities, while the seller was from the Shanghai branch of Huatai Securities [2]